Annual ROE
-58.61%
+94.09%+61.62%
December 31, 2023
Summary
- As of February 22, 2025, MRKR annual return on equity is -58.61%, with the most recent change of +94.09% (+61.62%) on December 31, 2023.
- During the last 3 years, MRKR annual ROE has risen by +46.37% (+44.17%).
- MRKR annual ROE is now -101.94% below its all-time high of 3017.11%, reached on December 31, 2014.
Performance
MRKR ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROE
-90.22%
-10.83%-13.64%
September 30, 2024
Summary
- As of February 22, 2025, MRKR quarterly return on equity is -90.22%, with the most recent change of -10.83% (-13.64%) on September 30, 2024.
- Over the past year, MRKR quarterly ROE has dropped by -10.83% (-13.64%).
- MRKR quarterly ROE is now -103.96% below its all-time high of 2280.07%, reached on June 30, 2002.
Performance
MRKR Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
MRKR ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +61.6% | -13.6% |
| 3 y3 years | +44.2% | -13.6% |
| 5 y5 years | +87.5% | -67.9% |
MRKR ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +61.6% | -145.3% | +22.2% |
| 5 y | 5-year | -41.4% | +61.6% | -145.3% | +22.2% |
| alltime | all time | -101.9% | +95.0% | -104.0% | +100.0% |
Marker Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | -90.22%(+13.6%) |
| Jun 2024 | - | -79.39%(+115.9%) |
| Mar 2024 | - | -36.78%(-26.6%) |
| Dec 2023 | -58.61%(-61.6%) | -50.14%(-3.9%) |
| Sep 2023 | - | -52.15%(-24.0%) |
| Jun 2023 | - | -68.58%(-40.9%) |
| Mar 2023 | - | -116.03%(+2.7%) |
| Dec 2022 | -152.70%(+60.4%) | -113.02%(+2.7%) |
| Sep 2022 | - | -110.00%(+6.4%) |
| Jun 2022 | - | -103.37%(+17.3%) |
| Mar 2022 | - | -88.13%(+22.1%) |
| Dec 2021 | -95.21%(-9.3%) | -72.20%(-4.3%) |
| Sep 2021 | - | -75.45%(+2.7%) |
| Jun 2021 | - | -73.45%(-2.3%) |
| Mar 2021 | - | -75.17%(-7.8%) |
| Dec 2020 | -104.98%(+153.3%) | -81.53%(+26.8%) |
| Sep 2020 | - | -64.30%(+19.7%) |
| Jun 2020 | - | -53.74%(+13.4%) |
| Mar 2020 | - | -47.37%(+14.2%) |
| Dec 2019 | -41.44%(-91.2%) | -41.48%(-88.3%) |
| Sep 2019 | - | -353.40%(-19.8%) |
| Jun 2019 | - | -440.56%(-29.3%) |
| Mar 2019 | - | -623.24%(-42.3%) |
| Dec 2018 | -469.72%(+110.5%) | -1080.78%(+115.6%) |
| Sep 2018 | - | -501.19%(+56.5%) |
| Jun 2018 | - | -320.20%(+24.8%) |
| Mar 2018 | - | -256.55%(+33.1%) |
| Dec 2017 | -223.15%(+462.1%) | -192.77%(+26.2%) |
| Sep 2017 | - | -152.77%(-73.0%) |
| Jun 2017 | - | -566.43%(-1802.5%) |
| Mar 2017 | - | 33.27%(+6.2%) |
| Dec 2016 | -39.70%(-124.9%) | 31.32%(+82.2%) |
| Sep 2016 | - | 17.19%(-110.6%) |
| Jun 2016 | - | -162.72%(-163.5%) |
| Mar 2016 | - | 256.24%(-33.1%) |
| Dec 2015 | 159.48%(-94.7%) | 383.19%(-56.0%) |
| Sep 2015 | - | 871.00%(-54.3%) |
| Jun 2015 | - | 1907.30%(+1172.4%) |
| Mar 2015 | - | 149.90%(-88.3%) |
| Dec 2014 | 3017.11%(+4681.5%) | 1282.64%(+65.0%) |
| Sep 2014 | - | 777.42%(+27.7%) |
| Jun 2014 | - | 608.89%(+5.0%) |
| Mar 2014 | - | 580.12%(+508.5%) |
| Dec 2013 | 63.10%(-38.2%) | 95.34%(+17.8%) |
| Sep 2013 | - | 80.91%(+1.2%) |
| Jun 2013 | - | 79.95%(-34.4%) |
| Mar 2013 | - | 121.92%(-11.9%) |
| Dec 2012 | 102.14% | 138.40%(+40.1%) |
| Sep 2012 | - | 98.82%(-16.1%) |
| Jun 2012 | - | 117.74%(+116.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2012 | - | 54.36%(-38.9%) |
| Dec 2011 | 58.63%(-35.8%) | 88.94%(+9.5%) |
| Sep 2011 | - | 81.21%(-16.9%) |
| Jun 2011 | - | 97.70%(-40.1%) |
| Mar 2011 | - | 162.98%(-24.6%) |
| Dec 2010 | 91.35%(-96.7%) | 216.19%(-75.6%) |
| Sep 2010 | - | 887.81%(-9.3%) |
| Jun 2010 | - | 978.32%(-56.8%) |
| Mar 2010 | - | 2265.34%(+81.4%) |
| Dec 2009 | 2796.16%(+3749.9%) | 1248.61%(+54.8%) |
| Sep 2009 | - | 806.48%(+18.6%) |
| Jun 2009 | - | 680.08%(+262.8%) |
| Mar 2009 | - | 187.43%(-13.5%) |
| Dec 2008 | 72.63%(-68.7%) | 216.63%(+1.8%) |
| Sep 2008 | - | 212.85%(+9.8%) |
| Jun 2008 | - | 193.78%(-6.5%) |
| Mar 2008 | - | 207.28%(-29.7%) |
| Dec 2007 | 232.35%(+434.4%) | 294.89%(+53.9%) |
| Sep 2007 | - | 191.58%(+24.8%) |
| Jun 2007 | - | 153.48%(+45.8%) |
| Mar 2007 | - | 105.26%(+113.7%) |
| Dec 2006 | 43.48%(-2.5%) | 49.26%(+8.7%) |
| Sep 2006 | - | 45.30%(+8.5%) |
| Jun 2006 | - | 41.75%(-25.8%) |
| Mar 2006 | - | 56.29%(+2.3%) |
| Dec 2005 | 44.58%(-59.5%) | 55.04%(-46.0%) |
| Sep 2005 | - | 101.98%(-13.1%) |
| Jun 2005 | - | 117.41%(-13.4%) |
| Mar 2005 | - | 135.64%(-33.1%) |
| Dec 2004 | 109.96%(-87.8%) | 202.63%(-58.0%) |
| Sep 2004 | - | 482.23%(-28.7%) |
| Jun 2004 | - | 676.05%(-23.2%) |
| Mar 2004 | - | 880.73%(-27.2%) |
| Dec 2003 | 897.76%(-177.0%) | 1209.97%(-43.5%) |
| Sep 2003 | - | 2143.39%(-100.9%) |
| Jun 2003 | - | -235.40 K%(+3612.5%) |
| Mar 2003 | - | -6340.79%(-44.8%) |
| Dec 2002 | -1166.32%(-324.5%) | -11.48 K%(-636.6%) |
| Sep 2002 | - | 2138.88%(-6.2%) |
| Jun 2002 | - | 2280.07%(+1919.0%) |
| Mar 2002 | - | 112.93%(-60.9%) |
| Dec 2001 | 519.59%(+126.0%) | 288.77%(+10.9%) |
| Sep 2001 | - | 260.47%(-29.6%) |
| Jun 2001 | - | 369.85%(-38.1%) |
| Mar 2001 | - | 597.15%(-1.7%) |
| Dec 2000 | 229.86%(-71.2%) | 607.21%(-44.8%) |
| Sep 2000 | - | 1100.16%(-6.3%) |
| Jun 2000 | - | 1174.04%(+222.5%) |
| Mar 2000 | - | 364.02% |
| Dec 1999 | 797.24% | - |
FAQ
- What is Marker Therapeutics annual return on equity?
- What is the all time high annual ROE for Marker Therapeutics?
- What is Marker Therapeutics annual ROE year-on-year change?
- What is Marker Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for Marker Therapeutics?
- What is Marker Therapeutics quarterly ROE year-on-year change?
What is Marker Therapeutics annual return on equity?
The current annual ROE of MRKR is -58.61%
What is the all time high annual ROE for Marker Therapeutics?
Marker Therapeutics all-time high annual return on equity is 3017.11%
What is Marker Therapeutics annual ROE year-on-year change?
Over the past year, MRKR annual return on equity has changed by +94.09% (+61.62%)
What is Marker Therapeutics quarterly return on equity?
The current quarterly ROE of MRKR is -90.22%
What is the all time high quarterly ROE for Marker Therapeutics?
Marker Therapeutics all-time high quarterly return on equity is 2280.07%
What is Marker Therapeutics quarterly ROE year-on-year change?
Over the past year, MRKR quarterly return on equity has changed by -10.83% (-13.64%)